Dr. Robert D. Schumaker, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 628
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: University of Texas Southwestern Medical School at Dallas
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license MD031458 · KY license 36598
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Health System, Inc Knoxville, TN
- Parkwest Medical Center Knoxville, TN
- Fort Sanders Regional Medical Center Knoxville, TN
- Physicians Regional Medical Center Powell, TN
- Morristown Hamblen Hospital Association Morristown, TN
Medical groups
- Tennessee Cancer Specialists PLLC (67 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 628
- Services billed
- 214,523
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 39,780 | 40 |
| Injection, ferric carboxymaltose, 1 mg | 24,750 | 12 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 17,100 | 13 |
| Injection, denosumab, 1 mg | 11,220 | 50 |
| Injection, ferric derisomaltose, 10 mg | 3,000 | 26 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,618 | 531 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,550 | 33 |
| Blood test, comprehensive group of blood chemicals | 1,509 | 521 |
| Insertion of needle into vein for collection of blood sample | 1,502 | 528 |
| Injection, ondansetron hydrochloride, per 1 mg | 988 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Knoxville, TN | 128 |
| Letrozole Other prescribers in Knoxville, TN | 56 |
| Acyclovir Other prescribers in Knoxville, TN | 42 |
| Ondansetron Hcl Other prescribers in Knoxville, TN | 38 |
| Eliquis (apixaban) Other prescribers in Knoxville, TN | 37 |
| Prochlorperazine Maleate Other prescribers in Knoxville, TN | 37 |
| Tamoxifen Citrate Other prescribers in Knoxville, TN | 35 |
| Revlimid (lenalidomide) | 34 |
| Imatinib Mesylate | 30 |
| Ibrance (palbociclib) | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 43 companies reported 141 payments worth $3,101 in total to this clinician.
| Food and Beverage | $3,001 |
|---|---|
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Seagen Inc. Apr 3, 2025 | Education in-kind | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $57,912 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neo…
Merck Sharp & Dohme LLC - CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca UK Limited - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.